1. Absence of detectable monkeypox virus DNA in 11, 000 English blood donations during the 2022 outbreak. Issue 4 (8th February 2023) Authors: Knight, Chanice; Andreani, Julien; Garrett, Neil; Winter, Mark; Golubchik, Tanya; Breuer, Judy; Reynolds, Claire; Brailsford, Susan R.; Harvala, Heli; Simmonds, Peter Journal: Transfusion Issue: Volume 63:Issue 4(2023) Page Start: 690 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Issue 10303 (4th September 2021) Authors: Liu, Xinxue; Shaw, Robert H; Stuart, Arabella S V; Greenland, Melanie; Aley, Parvinder K; Andrews, Nick J; Cameron, J Claire; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Dinesh, Tanya; England, Anna; Faust, Saul N; Ferreira, Daniela M; Finn, Adam; Green, Christopher A; Hallis, Bas... Journal: Lancet Issue: Volume 398:Issue 10303(2021) Page Start: 856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Issue 10318 (18th December 2021) Authors: Munro, Alasdair P S; Janani, Leila; Cornelius, Victoria; Aley, Parvinder K; Babbage, Gavin; Baxter, David; Bula, Marcin; Cathie, Katrina; Chatterjee, Krishna; Dodd, Kate; Enever, Yvanne; Gokani, Karishma; Goodman, Anna L; Green, Christopher A; Harndahl, Linda; Haughney, John; Hicks, Alexander; va... Journal: Lancet Issue: Volume 398:Issue 10318(2021) Page Start: 2258 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Issue 8 (August 2022) Authors: Munro, Alasdair P S; Feng, Shuo; Janani, Leila; Cornelius, Victoria; Aley, Parvinder K; Babbage, Gavin; Baxter, David; Bula, Marcin; Cathie, Katrina; Chatterjee, Krishna; Dodd, Kate; Enever, Yvanne; Qureshi, Ehsaan; Goodman, Anna L; Green, Christopher A; Harndahl, Linda; Haughney, John; Hicks, Al... Journal: Lancet infectious diseases Issue: Volume 22:Issue 8(2022) Page Start: 1131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗